Physician profile
Yuhan Lee
NPI 1861848434
$4,120.79
in general payments reported to CMS, 2019-2025
43 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.61 · 2020: $161 · 2021: $1,245 · 2022: $538 · 2023: $936 · 2024: $821 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.52 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $696.52 | 2021-2025 | |
| Lilly USA, LLC | $508.26 | 2020-2024 | Mounjaro, Zepbound |
| Mayne Pharma Commercial LLC | $391.45 | 2021 | |
| Exact Sciences Corporation | $326.01 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $276.20 | 2023-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $271.04 | 2020-2025 | Trelegy Ellipta |
| Horizon Therapeutics Plc | $170.32 | 2021-2023 | Krystexxa |
| Novo Nordisk INC | $131.93 | 2020-2023 | Wegovy |
| Mylan Pharmaceuticals INC. | $109.55 | 2021-2022 | |
| Abbott Laboratories | $103.77 | 2022-2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $99.83 | 2023-2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $83.73 | 2021 | |
| Pfizer INC. | $77.19 | 2023-2025 | |
| Mylan Specialty L.P. | $72.56 | 2023-2024 | Yupelri |
| Nestle Healthcare Nutrition INC. | $67.22 | 2021-2023 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yuhan Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.